J Clin Neurol.  2022 Jan;18(1):3-13. 10.3988/jcn.2022.18.1.3.

Impact of General Factors on Glioma Immunotherapy

Affiliations
  • 1Department of Neurosurgery, General Hospital of Central Theater Command of Chinese People’s Liberation Army, Wuhan, China
  • 2Department of Neurosurgery, Changzheng Hospital, Naval Medical University, Shanghai, China
  • 3Department of Neurosurgery, Changhai Hospital, Naval Medical University, Shanghai, China

Abstract

Glioma remains the most common malignant tumor in the brain and is also the most difficult to treat. Immunotherapy achieving long-lasting tumor remission in multiple cancer types has received considerable attention due to its potential to improve the treatment outcomes of patients with glioma. However, clinical trials have not yet demonstrated major improvements in prognoses, which might be attributable to the extrinsic components and intrinsic mechanisms involved in the tumor microenvironment and immune system. It is particularly noteworthy that there is emerging evidence that current routine treatment modalities and the physical and psychological characteristics of patients have different impacts on the efficacy of glioma immunotherapy. This article addresses how these factors interact with the host immune system and tumor microenvironment, and highlights their potential roles in glioma immunotherapy, with the ultimate goal of developing better immunotherapybased personalized medicine strategies.

Keyword

glioma; immunotherapy; standard of care; psychophysiological characteristics
Full Text Links
  • JCN
Actions
Cited
CITED
export Copy
Close
Share
  • Twitter
  • Facebook
Similar articles
Copyright © 2024 by Korean Association of Medical Journal Editors. All rights reserved.     E-mail: koreamed@kamje.or.kr